Study on the Treatment of Differentiated Thyroid Carcinoma with Anlotinib

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

November 1, 2024

Study Completion Date

June 30, 2025

Conditions

DTC - Differentiated Thyroid Cancer

Interventions

DRUG

Anlotinib hydrochloride

If intolerance occurs, the dose can be downregulated

Trial Locations (1)

Peking Union Medical College Hospital, Beijing

All Listed Sponsors

lead

Yansong Lin

OTHER